SLC5A2 and chronic kidney disease: The phase 2b double-blind randomized multicentred Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD) trial demonstrated the superiority of such combination therapy over SGLT2 inhibitor therapy alone in terms of albuminuria and systolic and/or diastolic blood pressure over 12 weeks [55].